Login
$ZVRA
$9.25 +$0.00 (0.0%) After hours

$ZVRA 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Results of Operations and Financial Condition

$37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA

05 Aug 2026 8-K: Results of Operations and Financial Condition

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA

05 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

At the 2026 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. (the “Company”) held on June 4, 2026 (the “Annual Meeting”), the stockholders of the Company voted on the following matters, which are described in detail in the Comp...

06 May 2026 8-K: Results of Operations and Financial Condition

Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025

16 Mar 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

BOSTON, Mass., Mar. 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreeme...

09 Mar 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

The Employment Agreement (“Agreement” is made and entered into effective as of March 9, 2026 by and between Zevra Therapeutics, Inc., a Delaware corporation (the “Company”), including its affiliates, parent, subsidiaries, successors, and...

17 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

(c) On December 11, 2025, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Timothy Sangiovanni, the Company’s current Senior Vice President, Finance and Corporate Controller and principal account...

02 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Celebration, FL – December 2, 2025– Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alic...

20 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Celebration, FL – November 20, 2025– Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financia...

05 Nov 2025 8-K: Results of Operations and Financial Condition

Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million

12 Aug 2025 8-K: Results of Operations and Financial Condition

Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million

29 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 29, 2025, Zevra Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) for the following purposes:

13 May 2025 8-K: Results of Operations and Financial Condition

Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million

07 Apr 2025 8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition +1 more

Celebration, FL – Apr. 7, 2025 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of...

11 Mar 2025 8-K: Results of Operations and Financial Condition

FY 2024 net revenue of $23.6 million, driven by record product net revenue of $10.2 million during

27 Feb 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Celebration, FL – Feb. 27, 2025 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into ...

06 Dec 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Celebration, Fla – Dec. 6, 2024 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced organizational changes ...

22 Nov 2024 8-K: Regulation FD Disclosure; Other Events

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

12 Nov 2024 8-K: Results of Operations and Financial Condition

FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial

20 Sep 2024 8-K: Regulation FD Disclosure; Other Events

MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support